Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

Eva Kimby; Steven P. Treon; Athanasios Anagnostopoulos; Meletios Dimopoulos; Ramon Garcia-Sanz; Morie A. Gertz; Stephen Johnson; Veronique LeBlond; Jean Paul Fermand; David G. Maloney; Giampaolo Merlini; Pierre Morel; Enrica Morra; Gwen Nichols; Enrique M. Ocio; Roger Owen; Marvin Stone; Joan Bladé

doi:10.3816/CLM.2006.n.013

Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

Eva Kimby, Steven P. Treon, Athanasios Anagnostopoulos, Meletios Dimopoulos, Ramon Garcia-Sanz, Morie A. Gertz, Stephen Johnson, Veronique LeBlond, Jean Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin Stone, Joan Bladé

Hematology

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Abstract

This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

Original language	English (US)
Pages (from-to)	380-383
Number of pages	4
Journal	Clinical Lymphoma and Myeloma
Volume	6
Issue number	5
DOIs	https://doi.org/10.3816/CLM.2006.n.013
State	Published - Mar 2006

Keywords

Bence Jones protein
Disease progression
Immunoglobulin M
Relapse

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3816/CLM.2006.n.013

Cite this

Kimby, E., Treon, S. P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M. A., Johnson, S., LeBlond, V., Fermand, J. P., Maloney, D. G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E. M., Owen, R., Stone, M., & Bladé, J. (2006). Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia. Clinical Lymphoma and Myeloma, 6(5), 380-383. https://doi.org/10.3816/CLM.2006.n.013

Kimby, E, Treon, SP, Anagnostopoulos, A, Dimopoulos, M, Garcia-Sanz, R, Gertz, MA, Johnson, S, LeBlond, V, Fermand, JP, Maloney, DG, Merlini, G, Morel, P, Morra, E, Nichols, G, Ocio, EM, Owen, R, Stone, M & Bladé, J 2006, 'Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia', Clinical Lymphoma and Myeloma, vol. 6, no. 5, pp. 380-383. https://doi.org/10.3816/CLM.2006.n.013

@article{50d2ccc80bad4999b2deb24d208252a1,

title = "Update on recommendations for assessing response from the Third International Workshop on Waldenstr{\"o}m's macroglobulinemia",

abstract = "This report by an international consensus panel updates current recommendations for defining clinical response in Waldenstr{\"o}m's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.",

keywords = "Bence Jones protein, Disease progression, Immunoglobulin M, Relapse",

author = "Eva Kimby and Treon, {Steven P.} and Athanasios Anagnostopoulos and Meletios Dimopoulos and Ramon Garcia-Sanz and Gertz, {Morie A.} and Stephen Johnson and Veronique LeBlond and Fermand, {Jean Paul} and Maloney, {David G.} and Giampaolo Merlini and Pierre Morel and Enrica Morra and Gwen Nichols and Ocio, {Enrique M.} and Roger Owen and Marvin Stone and Joan Blad{\'e}",

year = "2006",

month = mar,

doi = "10.3816/CLM.2006.n.013",

language = "English (US)",

volume = "6",

pages = "380--383",

journal = "Clinical Lymphoma and Myeloma",

issn = "1557-9190",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

AU - Kimby, Eva

AU - Treon, Steven P.

AU - Anagnostopoulos, Athanasios

AU - Dimopoulos, Meletios

AU - Garcia-Sanz, Ramon

AU - Gertz, Morie A.

AU - Johnson, Stephen

AU - LeBlond, Veronique

AU - Fermand, Jean Paul

AU - Maloney, David G.

AU - Merlini, Giampaolo

AU - Morel, Pierre

AU - Morra, Enrica

AU - Nichols, Gwen

AU - Ocio, Enrique M.

AU - Owen, Roger

AU - Stone, Marvin

AU - Bladé, Joan

PY - 2006/3

Y1 - 2006/3

N2 - This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

AB - This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

KW - Bence Jones protein

KW - Disease progression

KW - Immunoglobulin M

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33646546982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646546982&partnerID=8YFLogxK

U2 - 10.3816/CLM.2006.n.013

DO - 10.3816/CLM.2006.n.013

M3 - Article

C2 - 16640813

AN - SCOPUS:33646546982

SN - 1557-9190

VL - 6

SP - 380

EP - 383

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

IS - 5

ER -

Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this